Near-infrared laser adjuvant for influenza vaccine

Satoshi Kashiwagi, Jianping Yuan, Benjamin Forbes, Mathew L. Hibert, Eugene L.Q. Lee, Laura Whicher, Calum Goudie, Yuan Yang, Tao Chen, Beth Edelblute, Brian Collette, Laurel Edington, James Trussler, Jean Nezivar, Pierre Leblanc, Roderick Bronson, Kosuke Tsukada, Makoto Suematsu, Jeffrey Dover, Timothy BraunsJeffrey Gelfand, Mark C. Poznansky

Research output: Contribution to journalArticlepeer-review

34 Citations (Scopus)


Safe and effective immunologic adjuvants are often essential for vaccines. However, the choice of adjuvant for licensed vaccines is limited, especially for those that are administered intradermally. We show that non-tissue damaging, nearinfrared (NIR) laser light given in short exposures to small areas of skin, without the use of additional chemical or biological agents, significantly increases immune responses to intradermal influenza vaccination without augmenting IgE. The NIR laser-adjuvanted vaccine confers increased protection in a murine influenza lethal challenge model as compared to unadjuvanted vaccine. We show that NIR laser treatment induces the expression of specific chemokines in the skin resulting in recruitment and activation of dendritic cells and is safe to use in both mice and humans. The NIR laser adjuvant technology provides a novel, safe, low-cost, simple-to-use, potentially broadly applicable and clinically feasible approach to enhancing vaccine efficacy as an alternative to chemical and biological adjuvants.

Original languageEnglish
Article numbere82899
JournalPloS one
Issue number12
Publication statusPublished - 2013 Dec 11

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Near-infrared laser adjuvant for influenza vaccine'. Together they form a unique fingerprint.

Cite this